TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Sitryx Therapeutics
Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

Sitryx Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company is advancing its lead program SYX-5219, a first-in-class oral PKM2 modulator for atopic dermatitis, with Phase 1b trials planned for Q1 2026. Additionally, SYX-1042, an itaconate mimetic, completed Phase 1 studies and is positioned to move to Phase 2 patient efficacy studies in 2026.

Insights
LLY   neutral

Eli Lilly is mentioned as a specialist investor in Sitryx's funding syndicate, indicating strategic interest in the company's immunology programs. However, this is a passive investment relationship with no direct operational involvement disclosed.